



APPROACHING Deadline - 30 June 2025

We are approaching the end of the baseline data collection period.
Please ensure that the baseline information for all your patients has been entered into REDCap, as well as available site data.

MESSAGE FROM THE STUDY CHAIR

Dear Investigators,

We are pleased to announce a **THESUS-HF II Study Site Investigators Lunch**, to be held during the **ESC Congress in Madrid from 29 August to 1 September**. Lunch will take place either Friday 30th or Saturday 31st August at a venue near the conference centre. Further details to follow once confirmed.

The **PASCAR & Nigerian Cardiac Society Conference 2025, Abuja, Nigeria**, will take place **14 - 19 September 2025**. Please indicate your attendance by clicking on the link in the **MEETINGS 2025** section below, as well as your participation in the **THESUS-HF II Workshop Session on 16 September 2025, from 14:00 onwards**.

Regards,
Karen Sliwa (THESUS-HF II Principal Investigator)



SCORECARD INFORMATION

We are currently developing the scorecard template and will share further details soon.



PATIENT DATA COLLECTION

Please indicate the number of days data was collected by completing the Patient Data Collection Confirmation Form

[CLICK HERE TO COMPLETE](#)



[PASCAR & Nigerian Cardiac Society Conference 2025, Abuja, Nigeria 14 - 19 September](#)

Kindly take note: A **THESUS-HF II Study Session Meeting** will take place during the PASCAR & 54th Annual General Meeting and Scientific Conference, providing an opportunity for you to present feedback and an abstract related to the THESUS-HF II Study.

Date
16 September 2025

Time
From 14:00 Onwards
(Nigerian Standard Time)



SITE INFORMATION

Thank you to all those who completed the site information, sites who have not uploaded their site information yet, please do so **on REDCAP as soon as possible and no later than 30 June 2025**.



ABSTRACTS to be Presented at ESC Congress - Madrid

Congratulations to everyone! Two of the three THESUS-HF II Study abstracts accepted will be presented at the ESC Congress – Madrid. Please see details below.

Our heartfelt thanks go out to all the participating sites for their tremendous effort and dedication in making this study a success thus far.

The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II): Access to Care

- Abstract Number: 3509
- Session Title: Risk Factors and Prevention (1)
- Session Date: 30 August 2025
- Session Time: 08:15 – 09:00
- Location: Station 10 – Research Gateway

The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II): Management and In-Hospital Outcome

- Abstract Number: 3318
- Session Title: Epidemiology, Prognosis and Outcome in Chronic Heart Failure
- Session Date: 31 August 2025
- Session Time: 16:15 – 17:00
- Location: Station 4 – Research Gateway

Looking forward to seeing you there!!



ABSTRACTS SUBMITTED

Congratulations to everyone! Three THESUS-HF II Study abstracts have been submitted & accepted.

Our heartfelt thanks go out to all the participating sites for their tremendous effort and dedication in making this study a success thus far.

The THESUS-HF II Study abstracts were submitted to the following publications:

PRESENTED at ESC HFA, Belgrade 17 - 20 May 2025:
The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II):
Access to Care

ACCEPTED to ESC Congress, Madrid 29 Aug - 1 Sep:
The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II):
Access to Care

ACCEPTED to ESC Congress, Madrid 29 Aug - 1 Sep:
The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II):
In-hospital Outcomes



UPTITRATION SUB-STUDY REDCap PORTAL

Usage and Dosing of Guideline-Directed Medical Therapies in African Patients with Heart Failure with Reduced and Mildly Reduced Ejection Fraction

Guidelines recommend starting and quickly increasing guideline-directed medical therapy (GDMT) within six weeks of heart failure (HF) hospitalization to reduce rehospitalization and mortality risk. However, there is a gap between these recommendations and actual practices, leaving many patients with HFREF and HFmrEF in Africa on suboptimal therapy. This Sub-study aims to:

1. Assess the proportion of HFREF and HFmrEF patients initiating ACEI/ARB/ARNI, MRA, beta-blockers, and SGLT2i before hospital discharge.
2. Evaluate initiation of these medications within 30 days of discharge.
3. Evaluate initiation within 60 days of discharge.
4. Determine the proportion achieving target doses of ACEI/ARB/ARNI, MRA, and beta blockers at 180 days post-discharge compared to baseline.



[CLICK HERE to complete Sub-Study information on REDCap](#)



PASCAR THESUS-HF II Study Steering Committee

Principal Investigator: Karen Sliwa

Co-investigator: Albertino Damasceno, Charle Viljoen, Mahmoud Sani, Gad Cotter

Sub-investigator: Neusa Jessen, Simon Stewart



CAPE HEART INSTITUTE
Global Medicine

[Connect with PASCAR here](#)



NIGERIAN CARDIAC SOCIETY (NCS)

in collaboration with

PAN-AFRICAN SOCIETY OF CARDIOLOGY (PASCAR)

presents

54th

**ANNUAL
GENERAL MEETING
AND SCIENTIFIC CONFERENCE
ABUJA 2025**

THEME

**COST-EFFECTIVE INTERVENTIONS
FOR MITIGATING THE BURDEN OF
CARDIOVASCULAR
DISEASES IN AFRICA**

- Telemedicine and Digital Technology for Cardiovascular Care.
- Role of Primary Care and Community Health Workers in Cardiovascular Disease Prevention and Management.
- Taming the Scourge of Sudden Cardiac Death in Africa.

10 CME POINTS AVAILABLE.



14 - 19 September 2025



Shehu Musa Yar'adua Centre, Abuja

REGISTRATION & ABSTRACT PORTAL NOW OPEN

www.nigeriancardiacsociety.com